Trio of drugs may fight "triple negative" cancer (science daily)

PharmaLive.com (December 10, 2010) - resistance to medicines, a cocktail of triple-drug for breast cancer gene target triple negative and the risk of carpal tunnel syndrome patients are among the points highlights study to be presented by researchers at the Johns Hopkins Kimmel Cancer Center at the 33rd Annual CTRC - AACR San Antonio Cancer Symposium, held from 8 to 12 December.

In collaboration with cell cultures and mice models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three promising drugs for the treatment of what is known as triple negative cancer.

Women with these cancers are missing hormone receptor 3 - estrogen and progesterone and human epidermal growth factor 2 (HER2). Currently, the triple negative breast cancers treatments are limited to surgery, chemotherapy and radiotherapy, which provide some improvements, but overall prognosis.

In the new study, scientists at the Johns Hopkins University has begun with a drug called Entinostat, blocks the enzyme that happens to make regulatory genes in the DNA molecules and reactivates a gene called Retinoic acid receptor beta (RARß). Then they have added a drug called all Trans Retinoic acid (Alliance), linked to vitamin A, which binds to a protein made by the reactivated RARß gene. Overall, drug Alliance and gene RARß act as an impediment to the growth of cancer cells. Scientists completed the cocktail of drugs by conventional chemotherapy in low doses of doxorubicin or paclitaxel.

According to scientists, each of the three drugs used alone may have an effect on the Elimination of tumor cells but by combining tips the scale in favour of the Elimination of cells more.

Cells grown in laboratory tests have shown that triple therapy from the drop-down list box stopped the growth of multiple triple negative breast cancer cell lines more effectively as one of the only treatments. The combination therapy also rejuvenated RARß expression and strongly inhibited tumor growth in all three quarters mice grafted with breast tumor cells.

Researchers discuss potential clinical trials of the drop-down list box therapy hoping to start next year, says Nguyen k. Nguyen, a graduate student in cellular and molecular medicine at the Johns Hopkins University program.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Johns Hopkins Medical Institutions, via EurekAlert!, a service of AAAS.

Note: If no author is given, the source is cited for this.